IBB Price Prediction, iShares Biotechnology ETF AI Recommendations

Category: @Health
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Regeneron Pharmaceuticals (NASDAQ:REGN), Gilead Sciences (NASDAQ:GILD), IQVIA Holdings (NYSE:IQV), Moderna (NASDAQ:MRNA), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Sarepta Therapeutics (NASDAQ:SRPT), Incyte Corp (NASDAQ:INCY), Intra-Cellular Therapies (NASDAQ:ITCI).

Industry description

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Market Cap

The average market capitalization across the iShares Biotechnology ETF ETF is 6.27B. The market cap for tickers in the group ranges from 50.13M to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is RPHM at 50.13M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Biotechnology ETF ETF was 18%. For the same ETF, the average monthly price growth was 80%, and the average quarterly price growth was 385%. KNSA experienced the highest price growth at 18%, while FDMT experienced the biggest fall at -33%.


The average weekly volume growth across all stocks in the iShares Biotechnology ETF ETF was -46%. For the same stocks of the ETF, the average monthly volume growth was -67% and the average quarterly volume growth was -5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 78
Price Growth Rating: 49
SMR Rating: 90
Profit Risk Rating: 83
Seasonality Score: -14 (-100 ... +100)
View a ticker or compare two or three
Ad is loading...
published price charts
A.I. Advisor
published General Information

General Information

Category Health

iShares Trust400 Howard StreetSan Francisco